Table 1. Clinical characteristics of patient cohort in TMAs. The patient characteristics are shown for the calibration dataset of 60 pairs and 82 patients without neoadjuvant or adjuvant therapy and the validation dataset of 66 patients. n and SD denote a number and standard deviation, respectively.
| Calibration (n = 120) | Calibration (n = 82) | Validation (n = 66) | |||||
|---|---|---|---|---|---|---|---|
| Cases (n = 60) | Controls (n = 60) | Cases (n = 35) | Controls (n = 47) | Cases (n = 38) | Controls (n = 28) | ||
| Age at prostatectomy, mean (SD) | 61.6 (7.1) | 62.9 (6.5) | 62.2 (7.1) | 63.1 (6.7) | 63.1 (7.1) | 63.8 (5.3) | |
| Race, n (%) | White | 51 (85) | 51 (85) | 30 (85.7) | 40 (85.1) | 33 (86.8) | 25 (89.3) |
| African American | 9 (15) | 9 (15) | 5 (14.3) | 7 (14.9) | 4 (10.5) | 3 (10.7) | |
| Other | 1 (2.6) | ||||||
| Gleason sum, n (%) | ≤6 | 12 (20) | 12 (20) | 7 (20) | 10 (21.3) | 17 (44.7) | 6 (21.4) |
| 7(3 + 4) | 35 (58.3) | 35 (58.3) | 21 (60) | 28 (59.6) | 16 (42.1) | 15 (53.6) | |
| 7(4 + 3) | 7 (11.7) | 7 (11.7) | 6 (17.1) | 6 (12.8) | 4 (10.5) | 3 (10.7) | |
| ≥8 | 6 (10) | 6 (10) | 1 (2.9) | 3 (6.4) | 1 (2.6) | 4 (14.3) | |
| Pathological stage, n (%) | T2a | 7 (11.7) | 7 (11.7) | 4 (11.4) | 7 (14.9) | 2 (5.3) | 2 (7.1) |
| T2b | 33 (55) | 33 (55) | 18 (51.4) | 30 (63.8) | 26 (68.4) | 15 (53.6) | |
| T3a | 19 (31.7) | 19 (31.7) | 13 (37.1) | 10 (21.3) | 10 (26.3) | 11 (39.3) | |
| T3b | 1 (1.7) | 1 (1.7) | |||||
| Serum PSA ng/mL, mean (SD) | 10.6 (8.7) | 8.6 (6.0) | 10.4 (10.2) | 8.7 (6.1) | 9.5 (7.2) | 8.5 (4.8) | |
| Month to recurrence, mean (SD) | 38.6 (29.0) | 44.5 (33.1) | 36.6 (28.7) | ||||